Benedicte H. Fossum brings extensive expertise in vaccine development and life sciences. A trained veterinarian, Fossum was one of the founders of Pharmaq, the world’s leading provider of pharmaceuticals and vaccines for aquaculture. She has served on the board of Bionor Pharma, which worked toward an HIV vaccine, and holds broad experience from both private and publicly listed companies, including several successful IPOs.

Immuvera develops cancer therapy through combining validated immune therapy from human medicine with new routes of administration, firstly in companion animals, maintaining a low-risk focus and utilizing knowledge in comparative oncology.

Benedicte H. Fossum comments:

“If we get a proof of concept for the treatment or prevention of lung metastases in dogs, Immuvera Therapeutics is a company that will be very successful in markets where dogs are considered highly valued companion animals.” 

Jostein Christian Dalland adds deep experience in scaling technology and biotech ventures from concept to commercialization. He has led companies through IPOs, negotiated global partnerships, and secured major licensing agreements. With a strong governance background and a track record of creating structure and execution speed, Dalland will play a key role in guiding Immuvera’s strategic direction.

Jostein Christian Dalland comments:

“A less invasive treatment with lower risk and the potential for a better quality of life represents a very attractive international opportunity. The company has already done a solid job of identifying this, but in my opinion, the potential is even greater – especially when you see the opportunity for a global partner model in a market that may grow even faster than human medicine.”

Marcus Sahlin Pettersen, Chair of the Board, comments:

“We are delighted to welcome Benedicte and Jostein to the board. Their combined expertise in life sciences, commercialization, and governance will be invaluable as Immuvera advances toward clinical validation and international market entry.”

Immuvera Therapeutics is currently developing innovative treatments aimed at preventing and managing metastatic cancer in companion animals. With a strong scientific foundation and growing market demand, the company is poised to become a leading player in veterinary oncology.

In September, Immuvera also announced the addition of Gry Stensrud as Chief Technical Officer and Anja E. H. Holm as Head of Regulatory Affairs.